U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Medical Devices
  3. Medical Devices News and Events
  4. Webinar - Draft Guidance: Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle - 10/15/2024
  1. Medical Devices News and Events

Webcast | Virtual

Event Title
Webinar - Draft Guidance: Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle
October 15, 2024

Date:
October 15, 2024
Time:
1:00 PM - 2:00 PM ET

Summary

On October 15, 2024, the FDA will host a webinar for interested parties to answer questions about this draft guidance: Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle.

Add this to my Calendar
Outlook users: Click link, select Open, then click Save & Close

Background

When finalized, the guidance Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle is intended to provide recommendations on how patient preferences can be collected and shared with the FDA and be considered in decision-making. The guidance will also outline the types of patient preference studies that can provide reliable scientific evidence.

The FDA encourages medical device companies to use patient preference information to inform the entire product lifecycle. This includes considering what patients want to achieve with a treatment, what they're willing to tolerate in terms of risks, and what they value most. Patient preference information (PPI) can be applied throughout the entire product lifecycle, from early development to post-market evaluation.

Additionally, the FDA may include patient preferences information in its decision summaries for medical devices. This information can be used to:

  • inform FDA decision-making at various stages, helping to ensure that devices are safe and effective for patients.
  • help ensure patients are informed about the benefits and risks of a device and can make more informed decisions about their care.

Webinar Details

Registration is not necessary.

Date: October 15, 2024

Time: 1:00 P.M. - 2:00 P.M. ET

Please dial in 15 minutes before the start of the call to allow time to connect.

Please use the following link to join the webinar: https://fda.zoomgov.com/j/1603823633?pwd=QTSxWiqKO9eI2Uv7BaI9SUQfCXw7vs.1

Passcode:  ea!Tj1

Please note: Participants who join the webinar using the Zoom webinar link above should use computer audio (listen through their computer speakers and speaking through computer microphone/headset).

The dial-in information provided below is for participants who will be joining the webinar by phone only.

  • U.S. Callers Dial: 833-568-8864 (Toll Free)
    • For higher quality, dial a number based on your current location:
      • +1 669 254 5252 US (San Jose)
      • +1 646 828 7666 US (New York)
      • +1 646 964 1167 US (US Spanish Line)
      • +1 415 449 4000 US (US Spanish Line)
      • +1 551 285 1373 US
      • +1 669 216 1590 US (San Jose)
  • International Caller Dial: Please check the international numbers available
  • Webinar ID: 160 382 3633
  • Passcode: 154855

Webinar Materials

Following this webinar, the presentation and transcript will be available on CDRH Learn under "How to Study and Market Your Device", sub-section "Cross-Cutting Premarket Policy” as well.

If you have questions about this draft guidance document, please contact the CDRH Patient Preference Inbox at CDRH-PPI@fda.hhs.gov. If you have questions about this webinar, please contact CDRH's Division of Industry and Consumer Education (DICE) at dice@fda.hhs.gov, 1-800-638-2041, or 301-796-7100.

Back to Top